Rate Of Bacteremia Research Articles

Longevity and infection free survival of permicath

Abstract Background A hemodialysis catheter is a small biocompatible tube made of soft flexible material. It is inserted into a patient’s target vein to provide vascular access for hemodialysis. As important as catheter placing and handling guide-lines to prevent infection reporting standards are equally important, as they are the tools to enable us to evaluate our work attitudes, how much are we sticking to the guide-lines, how are we managing our resources, and are we aware of the resources we have or not. Aim of the Work to figure the outcome and infection rate related to tunneled-cuffed catheters in patients with ESRD needing dialysis who were submitted to tunneled cuffed catheter placement during the period from May 2017 to April 2018. Patients and Methods This retrospective descriptive study was conducted in 35 TTCs patients in the Vascular Surgery department ASU Hospital. Target population included patients of ESRD who were submitted for tunneled cuffed dialysis catheter placement in the Vascular Surgery department ASU Hospital in the period from May 2017 to April 2018. Results A total of 35 TCCs were inserted in end-stage renal disease patients for hemodialysis. Total number of catheter days was 6343 days. The primary unassisted patency rates at 6 months and 1 year were 51.4% and 11.4% respectively. Of the 35 cases 19 (54.28% of the total population) reported infection episode. 5 (26.3% of the infected population) TCCs were removed due to a severe episode of BSI, of the removed TCCs 2 (10.5% of the infected population) were died. The TCC bacteraemia rate was 2.186 per 1000 catheter days. The total number of the removed TCCs was 14 (40% of the total population). The reasons for removal were non-patency, infection, and completion of therapy with percentage of 22, 8%, 14.3%, and 2, 9% respectively. Conclusion Tunnelled cuffed haemodialysis catheters are vital line of treatment in patients requiring long term haemodialysis especially elderly population with weak vasculature or consumed peripheral accesses in which it is considered an access of choice.

Pneumococcal purpura fulminans in asplenic or hyposplenic patients: a French multicenter exposed-unexposed retrospective cohort study

BackgroundPneumococcal infections remain the main cause of overwhelming post-splenectomy infections, and purpura fulminans may develop in almost 20% of patients with overwhelming post-splenectomy infection. We aimed at describing the impact of asplenia/hyposplenia on the clinical features and the outcomes of adult patients admitted to the intensive care unit (ICU) for pneumococcal purpura fulminans.MethodsA 17-year national multicenter retrospective cohort study included adult patients admitted to 55 French ICUs for an infectious purpura fulminans from 2000 to 2016. Patients with pneumococcal purpura fulminans were analyzed according to the absence or presence of asplenia/hyposplenia.ResultsAmong the 306 patients admitted to the ICU for purpura fulminans, 67 (22%) had a pneumococcal purpura fulminans, of whom 34 (51%) had asplenia (n = 29/34, 85%) or hyposplenia (n = 5/34, 15%) and 33 (49%) had eusplenia. The prevalence of pneumococcal purpura fulminans was seven times higher in asplenic/hyposplenic patients compared to eusplenic patients with purpura fulminans (n = 34/39, 87% vs. n = 33/267, 12%; p < 0.001). The median time interval between the occurrence of asplenia/hyposplenia and ICU admission was 20 [9–32] years. Pneumococcal vaccine coverage was 35% in asplenic/hyposplenic patients. Purpura was more frequently reported before ICU admission in asplenic/hyposplenic patients (n = 25/34, 73% vs. n = 13/33, 39%; p = 0.01). The rate of bacteremia did not differ between asplenic/hyposplenic and eusplenic patients (n = 31/34, 91% vs n = 27/33, 82%; p = 0.261). SAPS II (60 ± 14 vs. 60 ± 18; p = 0.244) and SOFA (13 [1–5] vs. 14 [1–4, 6]; p = 0.48) scores did not differ between asplenic/hyposplenic and eusplenic patients. There were no significant differences between asplenic/hyposplenic and eusplenic patients regarding the rate of limb amputation (n = 9/34, 26% vs. 15/33, 45%; p = 0.11) and hospital mortality (n = 20/34, 59% vs. n = 15/33, 45%; p = 0.27).ConclusionsHalf of pneumococcal purpura fulminans episodes occurred in asplenic or hyposplenic patients. Pneumococcal vaccine coverage was reported in one third of asplenic/hyposplenic patients. Half of pneumococcal purpura fulminans episodes occurred more than 20 years after splenectomy. Outcomes of pneumococcal purpura fulminans did not show significant differences between patients with or without asplenia or hyposplenia, although the small number of patients included limited our power to detect potential differences between groups.

Successful control of an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae ST307 outbreak in a neonatal intensive care unit

BackgroundIn this study, we evaluated the genetic relatedness of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae (ESBL-KPN) isolates from an outbreak in a neonatal intensive care unit (NICU) in August 2017, We implemented an active countermeasure to control this outbreak successfully.MethodsThe incidence of healthcare-associated ESBL-KPN bacteremia was evaluated before and after initiating enhanced infection control (IC) practices in January 2018. Surveillance cultures were set up and monitored for neonates, medical personnel, and NICU environments. Molecular analyses, including pulse-field gel electrophoresis (PFGE), sequence typing, and ESBL genotyping, were performed for the isolated KPN strains.ResultsAfter implementing the enhanced IC procedures, the healthcare-associated bacteremia rate decreased from 6.0 to 0.0 per 1000 patient-days. Samples from neonates (n = 11/15, 73.3%), medical personnel (n = 1/41, 2.4%), and medical devices and the environments (6/181, 3.3%) tested positive for ESBL-KPN in the surveillance cultures in December 2017. Active surveillance cultures revealed that 23 of 72 neonates who were screened (31.9%) were colonized with ESBL-KPN between January and March 2018. All the isolates demonstrated closely related PFGE patterns and were identified as ST307 strain carrying the CTX-M-15 gene.ConclusionsContaminated NICU environments and medical devices, as well as transmission by medical personnel, appeared to be the source of the outbreak of ESBL-KPN infection. We employed an enhanced IC strategy during January–March 2018 and successfully controlled the clonal outbreak of CTX-M-15-positive KPN. ST307 has emerged as an important bacteremia-causing pathogen in the NICU and should be carefully monitored.

Consensus Report on Diagnosis, Treatment and Prevention of Infective Endocarditis by Turkish Society of Cardiovascular Surgery (TSCVS), Turkish Society of Clinical Microbiology and Infectious Diseases (KLIMIK), Turkish Society of Cardiology (TSC), Turkish Society of Nuclear Medicine (TSNM), Turkish Society of Radiology (TSR), Turkish Dental Association (TDA) and Federation of Turkish Pathology Societies (TURKPATH) Cardiovascular System Study Group

Infective endocarditis (IE) is rare, but associated with significant morbidity and mortality rates. Estimates of the incidence of IE in Turkey are compromised by the absence of population-based prospective studies. Due to the frequent presence of predisposing cardiac conditions and higher rates of nosocomial bacteremia in highrisk groups, the incidence of IE is expected to be higher in Turkey. Additionally, while IE generally affects older people in developed countries, it still affects young people in Turkey. In order to reduce the mortality and morbidity, it is critical to diagnose the IE to determine the causative agent and to start treatment rapidly. However, most of the patients cannot be diagnosed in their first visits, about half of them can be diagnosed after three months, and the disease often goes unnoticed. In patients diagnosed with IE, the rate of identification of causative organisms is significantly lower in Turkey than in developed countries. Furthermore, most of the centers do not perform some essential microbiological diagnostic tests as a routine practice. Some antimicrobials that are recommended as the first-line of treatment for IE, particularly antistaphylococcal penicillins, are not available in Turkey. These problems necessitate reviewing the epidemiological, laboratory, and clinical characteristics of IE in our country, as well as the current information about its diagnosis, treatment, and prevention together with local data. Physicians can follow patients with IE in many specialties. Diagnosis and treatment processes of IE should be standardized at every stage so that management of IE, a setting in which many physicians are involved, can always be in line with current recommendations. Study Group for Infective Endocarditis and Other Cardiovascular Infections of the Turkish Society of Clinical Microbiology and Infectious Diseases has called for collaboration of the relevant specialist organizations to establish a consensus report on the diagnosis, treatment, and prevention of IE in the light of current information and local data in Turkey.

Risk factors for bacteremia following endoscopic retrograde cholangiopancreatography

Aim: Bacteremia after endoscopic retrograde cholangiopancreatography (ERCP) is a serious complication, but its risk factors have not yet been clearly defined. In this study, we aimed to determine the incidence of bacteremia and associated risk factors after ERCP.Methods: This retrospective-cohort study was conducted between January 2017 and December 2018. Patients who had no signs of infection before the procedure and who developed bacteremia after the procedure were included in the study. For each patient who developed bacteremia, two randomized control patients who underwent ERCP and did not develop bacteremia were selected to compare risk factors, clinical and laboratory findings. Results: A total of 91 bacteremia attacks were detected in 86 of the 4237 patients who underwent ERCP procedure. Bacteremia rate after ERCP was 2%. In multivariate analysis, the age of the patient, presence of biliary tract cancer, cholecystitis / cholangitis, pancreatitis and biopsy were determined as significant risk factors for post-ERCP bacteremia (P=0.009, P&lt;0.001, P=0.008, P=0.002 and P=0.014 respectively). Conclusion: The development of bacteremia after ERCP significantly increases the risk of mortality. The mean age of the patients who died was older. This result supports the use of prophylactic antibiotics especially in elderly patients. We think that knowledge of potential ERCP complications and risk factors may help reduce the incidence and severity of complications.

Epidural-Related Fever and Maternal and Neonatal Morbidity: A Systematic Review and Meta-Analysis

Background: While epidural analgesia (EA) is associated with maternal fever during labor, the impact on the risk for maternal and/or neonatal sepsis is unknown. Objectives: The aim of this systematic review was to investigate the effect of epidural-related intrapartum fever on maternal and neonatal outcomes. Methods: OVID MEDLINE, OVID Embase, the Cochrane Library, Cochrane Controlled Register of Trials, and clinical trial registries were searched for randomized controlled trials (RCT) and observational cohort studies from inception to November 2018. A total of 761 studies were identified with 100 eligible for full-text review. Only articles investigating the relationship between EA and maternal fever during labor were eligible for inclusion. Study quality was assessed using the Cochrane’s Risk of Bias tool and National Institute of Health Quality Assessment Tool. Two meta-analyses – one each for the RCT and observational cohort groups – were performed using the random-effects model of Mantel-Haenszel to produce summary risk ratios (RR) with 95% CI. Results: Twelve RCTs and 16 observational cohort studies involving 579,157 parturients were included. RRs for maternal fever for the RCT and cohort analyses were 3.54 (95% CI 2.61–4.81) and 5.60 (95% CI 4.50–6.97), respectively. Meta-analyses of RR for maternal infection in both groups were infeasible given few occurrences. Meta-analysis of data from observational studies showed an increased risk for maternal antibiotic treatment in the epidural group (RR 2.60; 95% CI 1.31–5.17). For both analyses, neonates born to women with an epidural were not evaluated more often for suspected sepsis. Neither analysis reported an increased rate of neonatal bacteremia or neonatal antibiotic treatment after EA, although data precluded conclusiveness. Conclusion: EA increases the risk of intrapartum fever and maternal antibiotic treatment. However, a definite conclusion on whether EA increases the risk for a proven maternal and/or neonatal bacteremia cannot be drawn due to the low quality of data. Further research on whether epidural-related intrapartum fever is of infectious origin or not is therefore needed.

To reduce the current rates of catheter-related bacteremia after the implementation of the Zero programs: This is the challenge

To reduce the current rates of catheter-related bacteremia after the implementation of the Zero programs: This is the challenge

The "connecting vessel" sign: an imaging biomarker to differentiate ruptured infected (mycotic) intracranial aneurysm mimicking the CTA spot sign.

Infected (mycotic) intracranial aneurysms (IIA) are a prevalent source of morbidity in patients with systemic infection. Unlike saccular aneurysms, ruptured IIA frequently presents with intracerebral hemorrhage (ICH), and the appearance of ruptured IIA on CTA overlaps with the CTA "Spot Sign" (SS), an imaging finding in non-infectious, spontaneous ICH. The purpose of this study was to investigate the imaging and clinical features which may differentiate these two entities on CTA for which treatment strategies differ substantially. In an IRB-approved, retrospective case series, we compared 14 patients with confirmed IIA and 14 patients with positive SS due to other non-infectious etiology (SS(+) ICH). Clinical history, laboratory studies, and CTA reports and images were reviewed to define imaging characteristics of IIA and SS(+) ICH, including the diagnostic criteria for SS used in clinical trials. A total of 7/14 patients (50.0%) diagnosed with IIA had ICH at presentation. Of these, 3/7 patients (42.9%) with ruptured IIA and ICH met diagnostic imaging criteria of SS. The remaining 4/7 patients did not meet criteria due to presence of a connecting vessel. Compared with SS(+) ICH of non-infectious etiology, patients with ruptured IIA were younger (40.7 vs. 66.4years) and had higher rates of IVDU and bacteremia (p < 0.01) and lower rates of hypertension (p < 0.01). Hematoma volume was similar in both groups, but lobar location was more frequent in ruptured IIA (p = 0.06). Mortality at 1year from diagnosis was equally high in both groups (42.9%). This study characterizes ruptured IIA as an imaging mimic of SS and provides a framework for differentiating these lesions, allowing prompt diagnosis and appropriate treatment.

P815 Are hospitalised patients with inflammatory bowel disease at increased risk of invasive bacterial infections? Results from POLIBD 2-year cohort study

Abstract Background The disease itself as well as immunomodulatory and biological therapy are risk factors for invasive bacterial infections in patients with inflammatory bowel disease (IBD). However, there are limited data on risk factors for bacteraemia in the general population of hospitalised patients with inflammatory bowel disease. The aim of the study was to assess the rate of bacteraemia in hospitalised patients with Inflammatory Bowel Disease and risk factors. Methods An observational cohort of hospitalised patients with Inflammatory Bowel Disease, aged 23–65 years, from 2017 to 2019 in a large tertiary hospital localised in Rzeszow (south-eastern Poland). Patients with one or more positive blood culture were reviewed. Those with Carlson comorbidity index of 2 or greater were excluded. Basic descriptive statistic and logistic regression to evaluate risk factors for bacteraemia were used. Results Of 727 admitted patients, only 1.24% had bacteraemia (9/727) (8, Crohn’s Disease; 1, Ulcerative Colitis). The most common pathogens were Staphylococcus epidermidis (MRCNS - methicillin-resistant coagulase-negative Staphylococcus - strain resistant to all beta-lactam antibiotics: penicillins, penicillins with a B-lactamase inhibitor, cephalosporin and carbapenem) (4/9 patients) and Escherichia coli (3/9 patients). The mortality rate at 30 days of patients with bacteraemia was 0% (no deaths in IBD patients with bacteraemia observed). Longer hospitalisation (mean length of stay for patients with CD was 42 ± 33 vs. 7.95 ± 17.3, p &amp;lt;0.001; mean length of stay for a patient with UC 15 ± 23 vs. 6.25 ± 15.4, p = 0.004) was associated with an increased risk of bacteraemia. Older age was not associated with an increased risk of bacteraemia (P&amp;gt;0.05). In multivariate analysis, treatment with either anti-tumour necrosis factor α, purine analogues, steroids or amino salicylates was not associated with an increased risk of bacteraemia. Conclusion Prolonged hospitalisation, but not Inflammatory Bowel Disease-related treatment, is associated with an increased risk of bacteraemia in hospitalised patients with Inflammatory Bowel Disease.

Early mortality attributable to PICC-lines in 4 public hospitals of Marseille from 2010 to 2016 (Revised V3).

Introduction:Peripherally inserted central catheters (PICC-line) are devices inserted through peripheral venous access. In our institution, this technology has been rapidly adopted by physicians in their routine practice. Bacteremia on catheters remains an important public health issue in France. However, the mortality attributable to bacteremia on PICC-line remains poorly evaluated in France and in the literature in general. We report in our study an exhaustive inventory of bacteremia on PICC-line and their 30 days mortality, over a 7 years period.Material and methods:From January 2010 to December 2016, we retrospectively matched PICC-line registers of the radiology department, blood culture records of the microbiology laboratory and medical records from the Hospital Information Systems.Results:The 11,334 hospital stays during which a PICC-line was inserted were included over a period of 7 years. Among them, 258 episodes of PICC-line-associated bacteremia were recorded, resulting in a prevalence of 2.27%. Hematology units: 20/324 (6.17%), oncology units: 55/1375 (4%) and hepato-gastro-enterology units: 42/1142 (3.66%) had the highest prevalence of PICC-line related bacteremia. The correlation analysis, when adjusted by exposure and year, shows that the unit profile explains 72% of the variability in the rate of bacteremia with a P = .023. Early bacteremia, occurring within 21 days of insertion, represented 75% of cases. The crude death ratio at 30 days, among patients PICC-line associated bacteremia was 57/11 334 (0.50%). The overall 30-day mortality of patients with PICC-line with and without bacteremia was 1369/11334 (12.07%). On day 30, mortality of patients with bacteremia associated PICC-line was 57/258 or 22.09% of cases, compared to a mortality rate of 1311/11076, or 11.83% in the control group (P < .05, RR 2.066 [1.54–2.75]). Kaplan–Meier survival analysis revealed a statistically significant excess mortality between patients with PICC-line associated bacteremia and PICC-line carriers without bacteremia (P < .0007, hazard ratio 1.89 [1307–2709]).Conclusion:Patients with PICC-line associated bacteremia have a significant excess mortality. The implementation of a PICC-line should remain the last resort after a careful assessment of the benefit/risk ratio by a senior doctor.

First phenotypic and molecular characterization of clinical isolates of drug resistant Providencia rettgeri in Imo state, South-Eastern Nigeria.

Background: Nosocomial outbreak of drug resistant Enterobacteriaceae including those mediated by Providencia species has become a serious public health challenge across the globe – owing to the difficulty in selecting antibiotics for proper treatment especially in the face of resistance. The morbidity and mortality rate of bacteremia due to Providencia species could be high, especially among the elderly and those with pre-existing medical conditions. This study was aimed at determining the occurrence of multidrug resistance phenotypes in clinical isolates of Providencia rettgeri using both phenotypic and genotypic techniques. Methods: Clinical isolates were identified to be isolates of P. rettgeri using standard microbiological and biochemical techniques; and these were characterized with respect to antibiotic resistant patterns. Overall, 143 clinical isolates of non-duplicate P. rettgeri isolates were bacteriologically recovered from the clinical specimens which included blood/wound swab samples (n=108) and swabs from surgical instruments and suction devices (n=35). Antimicrobial susceptibility test (AST) was done using the modified Kirby-Bauer disk diffusion techniques as per the Clinical Laboratory Standard Institute (CLSI) criteria. The isolates were tested phenotypically for ESBL production by the double disk synergy test (DDST) method and the β-lactamase genes were identified using polymerase chain reaction. The strains were sequenced with ABI3500XL analyzer with a 50 cm array, using POP7. Sequences data generated were analyzed with Geneious version 9. 0. 5. Results: The result of AST showed that Providencia rettgeri isolates were resistant to ceftazidime, cefotaxime, ampicillin and tetracycline. Based on the DDST method, some of the Providencia rettgeri isolates were phenotypically confirmed to be ESBL positive (11%) and MBL positive (6%). The results of the molecular analysis showed that the P. rettgeri isolates harbored SHV genes (n=6; 12. 5%) which mediates ESBL production. However, none of the isolates harboured the CTX-M or TEM gene. Conclusion: Our study shows that the P. rettgeri isolates analyzed were multidrug resistant, and they also harbour some important phenotypes and/or genotypes that mediate the production of ESBL (extended spectrum beta-lactamase). This is the first report of ESBL detection in clinical isolates of P. rettgeri in Imo state, southeast Nigeria.

Duration of catheterisation and risk of bacteremia following temporary hemodialysis catheterisation

Aim: To analyse the risk of infection after temporary haemodialysis catheter. Results: 210 catheter insertions were done in 160 patients. Bacteremia occurred in 72 cases. For femoral catheters, bacteremia rate increased from 27% in first week to 73% by second week (P

Bacteraemia in Haematopoietic Stem Cell Transplant Recipients in a Single Tertiary Referral Centre

Bacteraemia is a common and one of the serious complications in haematopoietic stem cell transplantation (HSCT). To date, there are no published data on antibiotic resistance and clinical outcome among HSCT recipients in Malaysia. The aim of the present study was to analyse the prevalence, antibiotic resistance and clinical outcome of bacteraemia in HSCT recipients, within 100 days following transplantation. We retrospectively analysed the prevalence, antibiotic resistance pattern and mortality rate of early bacteraemia among HSCT recipients in a single centre over a 5-year period (2013-2017). Thirty patients of 85 HSCT recipients developed bacteraemia with 40 positive cultures resulting in prevalence of 47% (40/85). Gram negative bacteria (GNB) accounted for 60.5% of total isolates. Enterobacteriaceae and Coagulase negative Staphylococcus (CoNS) were the commonest pathogens isolated. GNB showed a high resistance rate to ciprofloxacin. Only 30% of recipients responded to first line empirical antibiotics for febrile neutropenia (FN). The mortality rate was 13.3% (4/30), of which 50% was attributed to multi-drug resistance (MDR) Acinetobacter and 25% to extended spectrum beta-lactamase (ESBL) Enterobacteriaceae. Bacteraemia is a frequent and life-threatening early complication among HSCT recipients with MDR GNB being the commonest cause of mortality. The high rate of resistance to ciprofloxacin and failure of the first line empirical antibiotics to treat FN calls for a thorough evaluation of the current antibiotic prophylaxis and empirical treatment protocols. These findings have important clinical implications regarding the use and selection of both prophylactic and empiric antibiotic regimens to treat FN.

Association between statewide adoption of the CDC's Core Elements of Hospital Antimicrobial Stewardship Programs and rates of methicillin-resistant Staphylococcus aureus bacteremia and Clostridioides difficile infection in the United States.

To measure the association between statewide adoption of the Centers for Disease Control and Prevention's (CDC's) Core Elements for Hospital Antimicrobial Stewardship Programs (Core Elements) and hospital-associated methicillin-resistant Staphylococcus aureus bacteremia (MRSA) and Clostridioides difficile infection (CDI) rates in the United States. We hypothesized that states with a higher percentage of reported compliance with the Core Elements have significantly lower MRSA and CDI rates. All US states. Observational longitudinal study. We used 2014-2016 data from Hospital Compare, Provider of Service files, Medicare cost reports, and the CDC's Patient Safety Atlas website. Outcomes were MRSA standardized infection ratio (SIR) and CDI SIR. The key explanatory variable was the percentage of hospitals that meet the Core Elements in each state. We estimated state and time fixed-effects models with time-variant controls, and we weighted our analyses for the number of hospitals in the state. The percentage of hospitals reporting compliance with the Core Elements between 2014 and 2016 increased in all states. A 1% increase in reported ASP compliance was associated with a 0.3% decrease (P < .01) in CDIs in 2016 relative to 2014. We did not find an association for MRSA infections. Increasing documentation of the Core Elements may be associated with decreases in the CDI SIR. We did not find evidence of such an association for the MRSA SIR, probably due to the short length of the study and variety of stewardship strategies that ASPs may encompass.

Prevalence of Bacteremia in Febrile Patients With Sickle Cell Disease: Meta-Analysis of Observational Studies.

Pneumococcal vaccination has decreased the bacteremia rate in both the general pediatric and sickle cell disease (SCD) populations. Despite this decrease, and an increasing concern for antibiotic resistance, it remains standard practice to obtain blood cultures and administer antibiotics in all febrile (>38.5°C) patients with SCD. We conducted a systematic review and meta-analysis of the available studies of the prevalence of bacteremia in febrile patients with SCD. We searched the medical literature up to November 2018 in PUBMED, EMBASE, and Web of Science with terms epidemiology, prevalence, bacteremia, and sickle cell anemia. We only included studies with patients after 2000, when the pneumococcal 7-valent conjugate (PCV7) vaccine became widely available. The prevalence of bacteremia [95% confidence interval (CI)] was calculated by dividing the number of positive blood cultures by the number of febrile episodes. The I2 statistic measured heterogeneity between prevalence estimates. Bias in our studies was quantified by the Newcastle-Ottawa Quality Assessment Scale. Our search identified 228 citations with 10 studies meeting our inclusion/exclusion criteria. The weighted prevalence of bacteremia across all studies was 1.9% (95% CI, 1.22%-2.73%), and for Streptococcus pneumoniae bacteremia, it was 0.31% (95% CI, 0.16%-0.50%). Risks for bacteremia except central lines could not be determined because of the low prevalence of the outcome. There appears to be a need to develop a risk stratification strategy to guide physicians to manage febrile patients with SCD based on factors including, but not limited to, history and clinical examination, vaccination status, use of prophylactic antibiotics, laboratory values, likely source of infection, and accessibility to health care.

Home or Away from Home: A Multi-Institution Study Comparing Medical Outcomes, Patient Perspectives, and Health-Related Quality of Life for Outpatient Versus Inpatient Management after Chemotherapy for Pediatric Acute Myeloid Leukemia

INTRODUCTION Pediatric acute myeloid leukemia (AML) requires intensive chemotherapy that results in prolonged periods of neutropenia, placing patients at significant risk for life threatening infection. Current supportive care guidelines strongly recommend hospitalization after chemotherapy completion until neutrophil recovery. While approximately 70% of United States (US) centers adhere to this recommendation, there are little data to support inpatient over outpatient management. Therefore, we compared clinical outcomes (Aim 1), patient experiences (Aim 2), and patient quality of life (QoL) (Aim 3), between the two strategies in a nationally representative sample of newly diagnosed AML patients &amp;lt;19 years old. METHODS Aim 1 employed retrospective, standardized chart abstraction for AML patients treated between 2011 and 2019 at 17 centers in the US. Patients were observed from their first course of chemotherapy through treatment completion, stem cell transplant, site transfer, relapse, or death. The unit of analysis was chemotherapy courses, the primary exposure was inpatient versus outpatient management, and primary outcomes were bacteremia and time to next treatment course. Only courses in which the patient met "discharge eligible" criteria were included (Figure 1). Analyses excluded Induction I given the low rate of outpatient management. Log-binomial regression was used to compare the bacteremia incidence and generalized linear regression was used to compare time to next course. Generalized estimating equations were used in overall analyses to account for correlation between courses from the same patient. For Aim 2, patients/ families at 9 centers underwent semi-structured interviews that were transcribed and analyzed using a conventional content analysis approach (InVivo). For Aim 3, parent proxies at 14 centers completed a PedsQL before the start of chemotherapy and then after neutrophil recovery but prior to the start of the subsequent course. Only one chemotherapy course per patient was considered. Only "discharge eligible" patients were included. Parent-proxy generic core QoL scores at the end of the chemotherapy cycle were compared by exposure group using analysis of covariance accounting for baseline scores. RESULTS 573 patients contributed 1188 treatment courses for Aim 1 (Figure 1). Mean age was 9 ±6 years, 47% were female, and AML was classified as low, intermediate, and high risk, respectively in 65%, 4%, and 31%, respectively. Overall rates of bacteremia were not significantly different in patients receiving outpatient versus inpatient management (23.8% vs 29.0%, RR 0.76, 95% CI: 0.56, 1.03; p=0.07). Days to next course also did not differ between the groups (30.2 vs. 31.6, adjusted difference -1.6, 95% CI: -3.2, 0.5; p=0.17). In Aim 2, 86 interviews in 57 families (39 inpatient, 18 outpatient) were performed. 86% of families receiving inpatient management expressed satisfaction and 85% receiving outpatient management expressed satisfaction. Dissatisfaction with inpatient management was driven by concerns for hospital acquired infections and separation from family. Dissatisfaction with outpatient management stemmed from stress of caring for a neutropenic child at home. Patients/families reporting satisfaction with outpatient management emphasized that the approach would not be appropriate for all families. For Aim 3, mean (±SD) parent proxy PedsQL score did not differ between outpatient (74.3 ±18.3) and inpatient management (70.3 ±19.2), adjusted mean difference 3.95, 95% CI: -5.57, 13.5. CONCLUSION In this nationally representative sample of AML patients, outpatient management had bacteremia rates similar to inpatient management, with no difference in time to the start of next treatment course or patient QoL. Semi-structured interviews revealed strong alignment between patient/family satisfaction and center discharge practice. However, families experiencing outpatient management note high stress in caring for profoundly neutropenic patients at home and that this strategy would not be suitable for all families. These clinical and patient-centered results suggest that outpatient management during neutropenia is a viable approach without excess risk for children with AML. However, implementation studies are needed to identify patient/family characteristics that portend a positive experience with an outpatient strategy. Disclosures Raetz: Pfizer: Research Funding. Rubnitz:AbbVie: Research Funding. Fisher:Pfizer: Research Funding; Astellas: Other: Data Safety Monitoring Board Chair for an antifungal study; Merck: Research Funding.

Impact of Primary Antibacterial Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML Patients

Introduction: Patients with acute myeloid leukemia (AML) have a high risk of infection during induction therapy due to the severity and duration of chemotherapy-induced neutropenia. As a result, the American Society of Clinical Oncology and the Infectious Diseases Society of America recommend fluoroquinolone prophylaxis in this patient population during induction therapy. The initial studies supporting the current guidelines showed decreased risk of neutropenic fever and systemic bacterial infections with fluoroquinolone prophylaxis but no mortality benefit. Notably, the use of fluoroquinolone prophylaxis is associated with colonization and infection with multidrug-resistant organisms, and these studies were conducted in areas with low rates of fluoroquinolone resistance. At our institution, the rates of fluoroquinolone resistance among the 3 most common causes of Gram-negative bacteremia (Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa) ranged from 17% to 45% among inpatients during the study period. We aimed to evaluate the efficacy of fluoroquinolone prophylaxis in a population with high rates of fluoroquinolone resistance. Methods: We performed a retrospective chart review of newly diagnosed adult AML patients who received induction therapy at Mount Sinai Hospital in New York, NY, from 6/1/2012 to 12/31/2016. Patients were excluded if they received antibiotics for &gt;4 days in the 1 week prior to induction therapy, developed a clinically or microbiologically documented infection (CDI or MDI) in the 2 weeks prior to induction therapy, did not develop neutropenia (defined as neutrophil count &lt; 500 cells/μL), or developed fever on the first day of neutropenia. Patients were followed for 6 months after initiation of induction therapy. The primary outcome was development of neutropenic fever. The secondary outcomes were development of infections, infection with multidrug-resistant organisms, and mortality. We used a time-varying (Simon-Makuch) statistical approach to categorize patients into the prophylaxis group or no prophylaxis group. We adjusted each outcome for gender, age at diagnosis, type of AML (de novo vs. secondary), and type of induction therapy. Results: Of the 95 included patients, 77 received primary fluoroquinolone prophylaxis and 18 did not receive any bacterial prophylaxis. There was no difference in median age, gender, or type of induction therapy between the prophylaxis and no prophylaxis groups (Table 1). Although more patients in the prophylaxis group had de novo disease (61% vs. 33%, p=0.003) and received inpatient induction therapy (88% vs. 56%, p=0.003), there was no difference in duration of neutropenia (28 vs. 23 days, p=0.349). There was no statistically significant difference in risk of febrile neutropenia (multivariable HR 1.41 [0.70 - 2.84], p=0.339) or mortality (multivariable HR 0.72 [0.35-1.48], p=0.371), with or without adjustment for baseline confounders. During the induction period and 6-month follow up, there was no difference in rates of bacteremia, invasive fungal infections, Clostridium difficile infections, CDI, MDI, or infection with fluoroquinolone-resistant or multidrug-resistant organisms (Table 2). Conclusions: Use of primary fluoroquinolone prophylaxis during AML induction therapy did not impact rates of neutropenic fever, infections, and antimicrobial resistance during induction and 6 month follow up. Similar to prior studies, fluoroquinolone prophylaxis also did not improve overall survival. This suggests that primary fluoroquinolone prophylaxis in this high-risk population provides neither benefit nor harm. Larger randomized controlled clinical trials are needed to further investigate this topic. Disclosures Jacobs: Ansun Biopharma, Inc.: Consultancy.

PSU5 ECONOMIC IMPACT OF PULMONARY ARTERY CATHETER UTILIZATION AMONG CARDIAC SURGERY PATIENTS: PERSPECTIVES FOR AN ACUTE CARE HOSPITAL AND AN INTEGRATED PAYER-PROVIDER HEALTH SYSTEM

A recent study demonstrated pulmonary artery catheter (PAC) use surrounding cardiac surgery is associated with a significant decrease in the incidence of new onset heart failure (HF) and respiratory failure (RF), while bacteremia and urinary infection complication rates significantly increased, as compared to patients that did not receive a PAC. We evaluated the economic impact of perioperative monitoring PAC utilization for adult cardiac procedures to support decision-making regarding PAC adoption for an acute care hospital and an integrated payer-provider health system. An Excel-based model was created to estimate the annualized savings for a US acute care hospital utilizing a monitoring PAC perioperatively for cardiac procedures during the index visit. A second model for an integrated payer-provider included costs for the index visit and for treatment of persistent index visit-related HF and RF complications over the following year (excluding patients with history of these conditions). Complication rates, costs, and healthcare utilization inputs were extracted from literature and a national database. Scenario analyses with varying surgical volume and PAC adoption rates were performed, as were one-way and probabilistic sensitivity analyses. For an acute care hospital, base-case (500 cardiac surgeries/year, 34% PAC adoption) annualized savings for the index visit totaled US$61,806 vs. no PAC utilization. Scenario analyses with cardiac surgical volumes of 100 and 1,500 procedures/year resulted in estimated savings of US$12,361 and US$185,418, respectively. Increased PAC adoption rates (75% and 95%) were associated with increased savings: US$134,751 and US$170,685, respectively, for 500 procedures/year. HF and RF treatment costs had the largest impact on savings. For an integrated payer-provider, base-case (3,845 cardiac surgeries/year, 34% PAC adoption) resulted in estimated savings of US$596,637 for the index visit and treatment of related complications over the following year. Monitoring PAC utilization for adult cardiac surgeries generates significant savings for acute care hospitals and integrated payer-provider systems.

Rate and Predictors of Bacteremia in Afebrile Community-Acquired Pneumonia

Although blood cultures (BCs) are the "gold standard" for detecting bacteremia, the utility of BCs in patients with community-acquired pneumonia (CAP) is controversial. This study describes the proportion of patients with CAP and afebrile bacteremia and identifies the clinical characteristics predicting the necessity for BCs in patients who are afebrile. Bacteremia rates were determined in 4,349 patients with CAP enrolled in the multinational cohort study The Competence Network of Community-Acquired Pneumonia (CAPNETZ) and stratified by presence of fever at first patient contact. Independent predictors of bacteremia in patients who were afebrile were determined using logistic regression analysis. Bacteremic pneumonia was present in 190 of 2,116 patients who were febrile (8.9%), 101 of 2,149 patients who were afebrile (4.7%), and one of 23 patients with hypothermia (4.3%). Bacteremia rates increased with the CURB-65 score from 3.5%in patients with CURB-65 score of 0 to 17.1%in patients with CURB-65 score of 4. Patients with afebrile bacteremia exhibited the highest 28-day mortality rate (9.9%). Positive pneumococcal urinary antigen test (adjusted OR [AOR], 4.6; 95%CI, 2.6-8.2), C-reactive protein level > 200mg/L (AOR, 3.1; 95%CI, 1.9-5.2), and BUN level≥ 30mg/dL (AOR, 3.1; 95%CI, 1.9-5.3) were independent positive predictors, and antibiotic pretreatment (AOR, 0.3; 95%CI, 0.1-0.6) was an independent negative predictor of bacteremia in patients who were afebrile. A relevant proportion of patients with bacteremic CAP was afebrile. These patients had an increased mortality rate compared with patients with febrile bacteremia or nonbacteremic pneumonia. Therefore, the relevance of fever as an indicator for BC necessity merits reconsideration.

562. Reducing MRSA Bacteremia in Adult Patients through MRSA Decolonization Bundle

BackgroundPatients colonized with methicillin-resistant Staphylococcus aureus (MRSA) are at an increased risk of developing a subsequent MRSA infection. Moreover, these individuals may serve as an endogenous reservoir to spread the bacteria to other patients. In an attempt to reduce MRSA bacteremia rates, a decolonization protocol was developed and implemented at a tertiary teaching hospital in Detroit, Michigan. In this study, we evaluate the intervention’s impact on community-onset (CO) and hospital onset (HO) MRSA bacteremia rates.MethodsInfection Control developed an MRSA decolonization bundle for adults that consisted of daily Chlorhexidine gluconate (CHG) bathing and twice-daily nasal swabs with 10% Povidone–iodine (PI) or Nozin for individuals with iodine allergies. Patients with known risk factors for developing an MRSA infection, such as patients residing in an intensive care unit and/or undergoing specified procedure, were prescribed the bundle for their length of stay (Figure 1). Countraindications for nasal decolonization included inhalation injuries, CSF leaks, ENT surgeries, and transphenoidal surgeries. A retrospective chart review of high-risk patients was conducted to determine compliance with the elements of the MRSA decolonization bundle. Rates of CO and HO MRSA bacteremia per 1,000 patient-days were graphed against compliance with bundle elements (2 nasal swabs and 1 CHG bath per day). To quantify the correlation, a linear regression model and the Pearson coefficient was used.ResultsApproximately 2,000 and 1,000 opportunities for nasal decolonization and CHG bathing, respectively, were identified between September 2018 and March 2019. The data suggest a strong correlation between compliance with MRSA decolonization elements and rate of HO MRSA bacteremia (R2 = 0.785) and a moderate association between nasal decolonization and rate of CO bacteremia (R2 = 0.322) (Figures 2 and 3).ConclusionThe MRSA decolonization bundle of CHG bathing and nasal swabs appears to be an effective strategy to decrease HO MRSA bacteremia rates with higher bundle compliance being associated with lower rates of infection. Disclosures All authors: No reported disclosures.